NASDAQ · BDTX
Healthcare · Biotechnology
$1.90
Up+$0.09 (+4.97%)
Updated Nov 5, 2026, 3:23 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BDTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
BDTX closed at $1.90 after 21 trading sessions, up 3.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.86 | $1.96 | $1.84 | $1.90 | 608.35K |
| Nov 3, 2026 | $1.76 | $1.85 | $1.76 | $1.81 | 332.02K |
| Nov 2, 2026 | $1.79 | $1.86 | $1.75 | $1.75 | 494.37K |
| Oct 30, 2026 | $1.85 | $1.90 | $1.76 | $1.78 | 520.16K |
| Oct 29, 2026 | $1.85 | $1.89 | $1.795 | $1.86 | 551.01K |
| Oct 28, 2026 | $1.74 | $1.87 | $1.705 | $1.83 | 1.04M |
| Oct 27, 2026 | $1.71 | $1.77 | $1.645 | $1.75 | 1.1M |
| Oct 26, 2026 | $1.89 | $1.90 | $1.67 | $1.69 | 862.92K |
| Oct 23, 2026 | $2.05 | $2.05 | $1.83 | $1.88 | 927.81K |
| Oct 22, 2026 | $2.06 | $2.105 | $2.03 | $2.08 | 790.96K |
| Oct 21, 2026 | $2.07 | $2.14 | $2.005 | $2.08 | 2.36M |
| Oct 20, 2026 | $1.82 | $2.14 | $1.82 | $2.07 | 2.11M |
| Oct 19, 2026 | $1.71 | $1.835 | $1.71 | $1.81 | 825.58K |
| Oct 16, 2026 | $1.75 | $1.75 | $1.675 | $1.72 | 539.76K |
| Oct 15, 2026 | $1.69 | $1.74 | $1.67 | $1.74 | 624.83K |
| Oct 14, 2026 | $1.67 | $1.76 | $1.63 | $1.70 | 1.07M |
| Oct 13, 2026 | $1.76 | $1.7698 | $1.60 | $1.68 | 1.14M |
| Oct 12, 2026 | $1.865 | $1.865 | $1.765 | $1.77 | 377.69K |
| Oct 9, 2026 | $1.81 | $1.83 | $1.79 | $1.83 | 448.97K |
| Oct 8, 2026 | $1.81 | $1.81 | $1.77 | $1.81 | 785K |
| Oct 7, 2026 | $1.79 | $1.87 | $1.775 | $1.83 | 563.5K |
The latest Smart Investors Daily articles mentioning BDTX.
Company
Market Activity
Research & News
BDTX research
Company profile and research snapshot.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 29, 2026 | BTIG | Buy | — |
| Mar 17, 2026 | Wedbush | Outperform | — |
| Jan 16, 2026 | Piper Sandler | Overweight | — |
| Dec 4, 2025 | Guggenheim | Neutral | — |
No generated briefing is available yet.
Benzinga · May 7, 2026
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
Finnhub · May 7, 2026
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Finnhub · May 7, 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
Benzinga · Apr 29, 2026
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDTX.
